Monoclonal Antibody Therapy
Novel COVID-19 monoclonal antibody therapy
Due to increased incidence of variant forms of SARS-CoV-2 which have greater resistance to monoclonal antibody monotherapies, as of March 23, 2021, it is now recommended that Utah providers exclusively use combination monoclonal antibody therapies.
In addition to Eligibility Criteria, there are a number of Inclusion Criteria as defined by the EUA that specify who is eligible for this novel treatment.
COVID-19 Research Studies and Trials
Several Utah-based clinical trials and studies are underway. Some of these are listed below:
University of Utah: covidplasmatrial.org, 801-587-7573. This study will test whether a transfusion of plasma that has antibodies from persons who have recovered from COVID-19 is a good treatment for patients with early COVID-19 illness. Getting plasma with COVID-19 antibodies may protect us against a severe COVID-19 infection, but we first need to conduct this study to know for sure. The study involves one plasma infusion within a day of enrollment with follow-up visits to a nearby facility (physical exam, swab test, lab tests) and telephone calls over 90 days and a symptom diary you fill out between visits.
University of Utah: covidplasmatrial.org, 801-587-7573. This study will test whether an infusion of plasma containing antibodies from recovered people can prevent uninfected people in a high-risk situation from developing COVID-19. If the trial proves to be successful, this treatment may help other people, who get exposed to the disease in the future, to not develop symptoms and possibly reduce the need for hospitalization. The study involves one plasma infusion at enrollment with follow-up visits to a nearby facility (physical exam, swab test, lab tests) and telephone calls over 90 days.
STOP COVID 2: https://stopcovidtrial.wustl.
UTAH ONE: https://utahcovidtrialsinfo.